Evobrutinib pathway to its major metabolite M463-2 and insights from a biotransformation and DDI perspective-Reference-Cited by-同舟云学术

Evobrutinib pathway to its major metabolite M463-2 and insights from a biotransformation and DDI perspective

Published:2023-09-02 Issue:8-9 Volume:53 Page:547-558
ISSN:0049-8254
Container-title:Xenobiotica
language:en
Short-container-title:Xenobiotica

Author:

Scheible Holger¹,Schieferstein Hanno¹,Schmidt Ralf²,Pusecker Klaus¹,Gradhand Ulrike¹,Gopalakrishnan Sathej³,Iqbal Khalid³,Dong Jennifer²,Jones Reinaldo²,Meli Claudia⁴,Bolleddula Jayaprakasam²,Dyroff Martin²,Georgi Katrin¹

Affiliation:

1. NCE DMPK Merck Healthcare KGaA, Darmstadt, Germany

2. EMD Serono Research & Development Institute, Inc, Billerica, MA, USA, an affiliate of Merck KGaA, Darmstadt, Germany

3. Quantitative Pharmacology Merck Healthcare KGaA, Darmstadt, Germany

4. Merck Ltd, Piedmont, Italy, an affiliate of Merck KGaA, Darmstadt, Germany

Funder

Merck Healthcare KGaA, Darmstadt, Germany

Publisher

Informa UK Limited

Subject

Health, Toxicology and Mutagenesis,Pharmacology,Toxicology,Biochemistry,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/00498254.2023.2272180

Reference17 articles.

1. Ability of Bruton’s Tyrosine Kinase Inhibitors to Sequester Y551 and Prevent Phosphorylation Determines Potency for Inhibition of Fc Receptor but not B-Cell Receptor Signaling

2. Clinical Pharmacokinetics and Pharmacological Effects of Carbamazepine and Carbamazepine-10,11-Epoxide

3. Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton’s Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases

4. Current Perspectives: Evidence to Date on BTK Inhibitors in the Management of Multiple Sclerosis

5. B cells in multiple sclerosis — from targeted depletion to immune reconstitution therapies

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Academic foreign compound metabolism – ‘ quo vadis ’?;Xenobiotica;2024-04-24